EURUSD Resistance lid holds tight at 1.1330

European Financial Stability Facility (EFSF) on Friday July 7

European Financial Stability Facility (EFSF) | Bond Yield 

FOREX INVESTORS  Euro Area EFSF decreased 0.01 percent or 0.01% to -0.39 on Friday July 7 from -0.39 in the previous trading session. Historically, the European Financial Stability Facility (EFSF) | Bond Yield reached an all time high of 2.57 in May of 2012 and a record low of -0.50 in January of 2017.

 Euro Area EFSF

European Financial Stability Facility (EFSF) | Bond Yield

The European Financial Stability Facility (EFSF) was created to safeguard financial stability in Europe by providing financial assistance to euro area Member States. The EFSF issues bonds or other debt instruments on the capital markets and its proceeds are then lent to countries under a macro economic programme. This page provides – European Financial Stability Facility (EFSF) | Bond Yield – actual values, historical data, forecast, chart, statistics, economic calendar and news. European Financial Stability Facility (EFSF) | Bond Yield – actual data, historical chart and calendar of releases – was last updated on July of 2017.

 

Actual Previous Highest Lowest Dates Unit Frequency
-0.39 -0.39 2.57 -0.50 2012 – 2017 percent Daily

Like up on FACEBOOK


logo



major currencies: (EUR-USD) (USD-JPY) (USD-GBP) (USD-CHF), (USD-CAD), (AUD-USD) (USDCNY)

European Shares Seen Up uropean stocks are set to open higher on Monday as investors took weak Chinese data in their stride

European Financial Stability Facility (EFSF)

European Financial Stability Facility (EFSF) | Bond Yield  

BUZ INVESTORS  Euro Area EFSF decreased 0.01 percent or 0.01% to -0.46 on Friday June 23 from -0.45 in the previous trading session. Historically, the European Financial Stability Facility (EFSF) | Bond Yield reached an all time high of 2.57 in May of 2012 and a record low of -0.50 in January of 2017.




 Euro Area EFSF

European Financial Stability Facility (EFSF) | Bond Yield

The European Financial Stability Facility (EFSF) was created to safeguard financial stability in Europe by providing financial assistance to euro area Member States. The EFSF issues bonds or other debt instruments on the capital markets and its proceeds are then lent to countries under a macro economic programme. This page provides – European Financial Stability Facility (EFSF) | Bond Yield – actual values, historical data, forecast, chart, statistics, economic calendar and news. European Financial Stability Facility (EFSF) | Bond Yield – actual data, historical chart and calendar of releases – was last updated on June of 2017.

 

Actual Previous Highest Lowest Dates Unit Frequency
-0.46 -0.46 2.57 -0.50 2012 – 2017 percent Daily

Like up on FACEBOOK


logo



major currencies: (EUR-USD) (USD-JPY) (USD-GBP) (USD-CHF), (USD-CAD), (AUD-USD) (USDCNY)




Buz Investors Canabo Medical Inc. Opens New Clinic i- Canabo Medical Inc. (TSX VENTURE: CMM) (OTCQB: CAMDF) ("Canabo" or the "Company") is pleased to announce it has opened a clinic in Chilliwack, British Columbia

Canabo Opens Second Nova Scotia Clinic and Announces Appointment of Garry Stewart as Chief Financial Officer

Canabo Opens Second Nova Scotia Clinic and Announces Appointment of Garry Stewart as Chief Financial Officer

 

 Canabo Opens Second Nova Scotia Clinic  Canabo Medical Inc. <span data-recalc-dims=(TSXV:CMM) (OTCQB: CAMDF) (“Canabo” or the “Company”) is pleased to announce it has opened its second clinic in Nova Scotia" width="300" height="300" srcset="https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/iszoKIoU.png?resize=300%2C300 300w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/iszoKIoU.png?resize=150%2C150 150w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/iszoKIoU.png?resize=65%2C65 65w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/iszoKIoU.png?w=450 450w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ INVESTORS  PRESS RELEASE  Canabo Opens Second Nova Scotia Clinic  Canabo Medical Inc. (TSXV:CMM) (OTCQB: CAMDF) (“Canabo” or the “Company”) is pleased to announce it has opened its second clinic in Nova Scotia for a total of 22 clinics and partner clinics nation-wide. The new clinic, located in Wolfville, Nova Scotia is now accepting referrals. As the second clinic for the province of Nova Scotia, this opening represents a broadening of Canabo’s national clinic footprint.

As previously discussed on June 5 in the Company’s Corporate Update, the clinic reports new patient volumes continue at record levels.

Dr. Neil Smith, Executive Chairman of Canabo Medical Inc. stated, “As explained in our June 5th Corporate Update we reiterate, there was no fundamental reason for the sharp decline in our share price during May. The Company’s operating fundamentals and growth trajectory remain strong.”




Canabo Opens Second Nova Scotia Clinic

Canabo also announces today the appointment of Mr. Garry Stewart as Chief Financial Officer.

Mr. Stewart is a Chartered Professional Accountant who brings over 25 years of professional experience to the role. Prior to joining Canabo, Mr. Stewart served as CFO, Vice President Finance at TAR Investments Ltd., including Datarite Ltd. and Atlantic Business Interiors Ltd.

Mr. Stewart replaces Mr. Rob Randall as Chief Financial Officer. Mr. Randall is leaving Canabo to focus on his other CFO roles but will continue to support and assist Mr. Stewart during the transition. John Philpott, President & CEO of Canabo, commented “I would like to thank Rob for his service to Canabo. He played a key role in the RTO transaction as well as the growth of the business. We wish him well in his future endeavours.”

About the Company

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis.  Established in 2014, Canabo now has 22 clinics across Canada, with additional locations planned to open in 2017.  Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




mCig Strengthens Share Structure, Announces Shareholder Call

$MCIG Announces (Unaudited) Fiscal Year 2017 Financial Results

|Chart | Calendar   | TRADE NOW | MCIG 

mCig, Inc. Announces (Unaudited) Fiscal Year 2017 Financial Results — Best Year in Corporate History

 

 

BUZ INVESTORS PRESS RELEASE Fiscal Year 2017 Financial Results mCig, Inc., ( OTCQB : (MCIG ), a leading BUZ INVESTORS  PRESS RELEASE  Fiscal Year 2017 Financial Results  mCig, Inc., ( OTCQB : (MCIG), a leading distributor of innovative products, technologies, and services for the global medical cannabis industry is pleased to announce some highlights of its year-end financial results:

Net Sales increased to $4.5 million, a 158% increase year to year comparison, and a 1,294% increase for the 4th quarter compared to same period last fiscal year
Net income of $1.5 million compared to a $1.4 million loss from the previous year, and an increase of $2.9 million net earnings
Cash and cash equivalents of $1.6 million compared to $0.1 million from the previous year (a 1,369% increase), and a 400% increase from last quarter. mCig generated $2.1 million in cash from operating activities
(mCig) assets increased to $6.8 million, having 6 times more assets than it does liabilities
In addition to the highlights mentioned above, mCig Inc. was able to reduce its operating expenses by $730K (43%) from the previous year. In addition, mCig increased its gross profit by 20% to 36% compared to 16% from the previous year.

mCig’s top three reporting segments were all profitable and have established a niche market for their respective products and services. An overview of the three segments are as follows:

 Fiscal Year 2017 Financial Results

Segment Sales Net Income
Construction $2.4M $212K
CBD $1.2M $888K
e-Cig $870K $143K

“We are proud to report a strong record year for mCig and its shareholders. With sales and profits soaring at exponential rates, our cash position increasing, more than $14M in backlog sales, our new and innovative solutions that are projected to have a significant impact on our future financial statements, the 616% CAGR for our shareholders, and still NO TOXIC DEBT, the MCIG story is bright,” says Paul Rosenberg, the company’s Chief Executive Officer. He went on to say, “We have just touched the tip of the iceberg and are thrilled with the strong momentum of our businesses.”

About MCIG Group ( OTCQB : MCIG )
Headquartered in Henderson, Nevada, mCig, Inc. ( OTCQB : MCIG ) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. mCig, Inc. is committed to being the leading distributor of technology, products, and services to fit the needs of a rapidly expanding industry. mCig, Inc. has transitioned from a vaporizer manufacturer to industry leading large scale, full service cannabis cultivation construction company with its Grow Contractors division currently operating in the rapidly expanding Nevada market.

mCig, Inc. also employs a world renowned tech team and has recently entered the tech space to satisfy its evolving role in technology and in keeping it’s growing following up to speed.

The company looks forward to growing its core competencies to service the ancillary legal Cannabis, Hemp and CBD markets, with broader expansion to take place once federal laws change. With over seventy five years of experience combined between the key players that make up the Cannabis Grow Contractors Division, mCig Inc. is proud to work with Cannabis Industry leaders and provide broad and rounded solutions for legal growers nationwide.

About the 420 Cloud App

The 420 Cloud app features a useful and unified cross-channel platform comprised of numerous layers of subscriber functions and behaviors, an immersive experience extremely useful for networking and learning, a technically robust 420 cannabis jobs search system (420jobsearch.com), marijuana news media platform (weedistry.com) and integrates a commerce networking platform, strengthening reach and exposure throughout it’s various channels. The platforms feature a full scale, cross-channel, ad network, spread throughout an enterprise of intuitive systems, scalable for high traffic and utilize big data conversion for monetization and analytics. The app plans to create revenue through gamification, advanced functions, features and micro-transactions, along with ads and partnerships with dispensaries.

The successful app market has grown from $45 billion in 2015 to $76 billion in 2017, and the marijuana market totaled $6.7 billion in 2016 and growing according to Forbes. In addition to current endeavors with large scale marijuana grow construction (growcontractors.org), mCig, Inc.’s alignment with these growing industries can greatly benefit the company’s growth and revenues.

About the Development Team

Having acquired part of the former Megaupload development team, a tech team with an impressive and proven track record, mCig is able to build an enterprise platform to accommodate scalability, performance and growth. The team is led by Chief Technologist, Andrus Nomm, recognized as the senior operative and programming lead in the popular online file sharing, streaming and ad serving websites of MEGAupload, MEGAclick and MEGAvideo. The sites served approximately 50 million users per day over 6500+ servers, monetizing over a quarter billion USD in advertising and subscription revenue.

Business Description

Industry: Tobacco Products » Tobacco    NAICS: 312230    SIC: 2111
Compare: NYSE:(AOI), OTCPK:(BXNG), OTCPK:(GLLA), OTCPK:(VPRB), OTCPK:(SRUP), OTCPK:(VAPI), OTCPK:(RCGR), OTCPK:(NHLE), NYSE:(TPB), NYSE:(UVV), NYSE:(VGR), OTCPK:(SWMAY), OTCPK:(GGNPF), OTCPK:(IMBBF), OTCPK:(JAPAY), NYSE:(RAI), OTCPK:(BTAFF), NYSE:(MO), NYSE:(PM) » details
Traded in other countries: M06.Germany,
Headquarter Location: USA

mCig Inc is a technology company. It is engaged in manufacturing and retailing of loose-leaf Ecig.

mCig Inc was incorporated in the State of Nevada on December 30, 2010 originally under the name Lifetech Industries, Inc. Effective August 2, 2013, the name was changed from Lifetech Industries, Inc. to mCig, Inc. The Company manufactures and retails the mCig, an affordable loose-leaf eCig. It provides a smoking experience by heating plant material, waxes, and oils delivering, in the Company’s opinion, a smoother inhalation experience. It operates in two two long-term secular trends: The decriminalization and legalization of marijuana for medicinal or recreational purposes – legalizing medicinal and recreational marijuana usage is steadily on the rise not only domestically but also internationally, The adoption of electronic vaporizing cigarettes (commonly known as “eCigs”), as smokers move away from traditional cigarettes onto e-cigarettes. Smoking tobacco causes numerous health problems, including disease and death. It competes with other sellers of electronic cigarettes, notably Lorillard, Inc., Altria Group, Inc. and Reynolds American Inc.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

BUZ INVESTORS big stock bonuses A year ago, Peabody Energy Corp's BTUUQ.PK chief executive was presiding over $2 billion of losses

Peabody Reports Earnings For Quarter Ended March 31, 2017; Revises Financial Targets For Full-Year 2017

|Chart | Calendar   | TRADE NOW | Peabody Energy

36px) Fz(25px)--sm Fz(32px) Mb(17px)--sm Mb(20px) Mb(30px)--lg Ff($ff-primary) Lts($lspacing-md) Fw($fweight) Fsm($fsmoothing) Fsmw($fsmoothing) Fsmm($fsmoothing) Wow(bw)" data-reactid="3">Peabody Reports Earnings For Quarter Ended March 31, 2017; Revises Financial Targets For Full-Year 2017

BUZ INVESTORS PRESS RELEASE Peabody Reports Earnings Revenue, income from continuing operations net of income taxes, net income, and Adjusted EBITDAR1

BUZ INVESTORS PRESS RELEASE  Peabody Reports Earnings Revenue, income from continuing operations net of income taxes, net income, and Adjusted EBITDAR1 all rise substantially on higher PRB shipments and increased Australian thermal and metallurgical coal pricing; net income reaches highest level in nearly five years; 2017 targets revised to reflect higher met coal volumes from full year of contributions from the Metropolitan hard coking coal mine.

Peabody (BTU) announced today that first quarter 2017 revenues, net income and Adjusted EBITDAR all showed substantial increases over the first quarter of 2016.  Revenues increased 29 percent to $1.33 billion.  Net income attributable to common stockholders increased $287.2 million to $122.1 million, the highest net income in nearly five years, and income from continuing operations net of income taxes rose $292.7 million to $131.0 million.  Adjusted EBITDAR increased $304.9 million to $390.0 million.

Peabody today also revised its full-year financial targets to reflect higher metallurgical coal volumes even in the aftermath of Cyclone Debbie in Australia.  The company is retaining the Metropolitan hard coking coal mine and its associated 16.67 percent interest in Port Kembla Coal Terminal in the company’s portfolio, after proposed purchaser South32 was unable to obtain regulatory clearance and terminated the purchase contract last month.

The company adopted fresh-start accounting under applicable accounting rules as of the April 3, 2017, effective date of the company’s plan of reorganization, which is not reflected in these first quarter results.  The adoption of fresh-start accounting may materially affect its results of operations following the fresh-start reporting dates, as the company will have a new basis in its assets and liabilities.  As a result, certain balance sheet and income statement items will not be comparable to previously reported historical results, including the first quarter 2017 results presented here.

“Peabody’s first quarter results were significantly improved over the prior year across the platform, reflecting sharply higher coal demand in the United States and expanded Australian margins for both thermal and metallurgical coal,” said Peabody President and Chief Executive Officer Glenn Kellow. “Whilst several temporary issues in Australia prevented the quarter from meeting our full potential, our performance was greatly improved with excellent cash generation from our operations.  We look forward to advancing with a strengthened balance sheet, rebounding shipments in Queensland, and retention of the Metropolitan Mine in New South Wales.”




Peabody Reports Earnings

>>>TRADE NOW<<<

4px) My(1.4em) Ov(a) canvas-atom" data-type="table" data-reactid="17">

Note: All comparisons are to first quarter of 2016 unless otherwise noted.

1 Adjusted EBITDAR is a non-GAAP financial measure. Please refer to the tables in this press release for a reconciliation of non-GAAP financial measures. 

First Quarter Results

First quarter revenues rose 29 percent to $1.33 billion (from $1.03 billion in the prior year), driven by a 26 percent increase in Powder River Basin shipments, 17 percent rise in Western sales volumes, and 139 percent and 44 percent average revenue-per-ton increases in Australian metallurgical and thermal coal, respectively.

First quarter 2017 net income attributable to common stockholders increased $287.2 million to $122.1 million, and reflected $93.3 million in lower interest expense associated with the impact of interest under certain debt instruments being stayed during the Chapter 11 proceedings, partly offset by $61.3 million in reduced tax benefits.

Quarterly income from continuing operations net of income taxes increased $292.7 million to $131.0 million, led by a 29 percent increase in revenues that outpaced a 5 percent increase in operating costs and expenses.

First quarter Adjusted EBITDAR rose to $390.0 million, a $304.9 million increase over the first quarter of 2016.  Adjusted EBITDAR included approximately $30 million in negative first quarter impacts from Cyclone Debbie in Australia and a $20 million benefit associated with the sale of the company’s 37.5 percent interest in the Dominion Terminal Associates in Virginia as part of the company’s ongoing portfolio management process.

Within consolidated Adjusted EBITDAR:

    d)" data-type="list" data-reactid="26">
  • U.S. Adjusted EBITDA increased 24 percent to $191.7 million, with improvements led by higher Powder River Basin and Western shipments, partly offset by reduced margins at Midwestern operations and a $13 million benefit related to a contractual resolution with a Southwestern U.S. coal customer.  Sales volumes, revenues per ton and costs per ton were all consistent with the company’s prior annual financial targets.
  • Australian Adjusted EBITDA rose to $185.2 million from $5.6 million in 2016, driven by a 139 percent increase in metallurgical coal revenues to $150.22 per ton, as well as a 44 percent increase in thermal coal revenues to $48.65 per ton.  Operating costs per ton rose 35 percent in Australian metallurgical mining, led by the impacts of Cyclone Debbie, temporary geologic and operating issues at several operations, and increased royalties due to higher prices.
  • Trading and Brokerage Adjusted EBITDA increased to $25.4 million from a loss of ($18.8) million in 2016, benefitting from realized profits on hedge positions taken in prior periods.

“With profitable operations across the U.S. and Australian platforms, Peabody looks forward to generating cash, further reducing debt and returning cash to shareholders over time,” said Peabody Executive Vice President and Chief Financial Officer Amy Schwetz.  “We have a new capital structure and focused capital discipline that is designed to serve shareholders well through all cycles.”

2017 Targets

Sales Volumes (short tons)

Australia Operations – Costs Per Ton (USD)3

PRB

115 – 120 million

Metallurgical

$85 – $95

ILB

18 – 20 million

Thermal

$31 – $35

Total U.S.

145 – 155 million

Total Australia

$51 – $54

Australia Metallurgical1

11 – 12 million

Capital Expenditures

$165 – $195 million

Australia Export Thermal2

13 – 14 million

Australia Domestic Thermal

~8 million

Q2 – Q4 2017 Cost Sensitivities4

Total Australia

32 – 34 million

$0.05 Decrease in A$ FX Rate5

+~$70 – $75 million

$0.05 Increase in A$ FX Rate5

– ~$30 – $35 million

Trading and Brokerage

3 – 7 million

Fuel (+/- $10/barrel)

+/- ~$24 million

Total Tons Sold

180 – 196 million

Priced Position

PRB Tons 

~115 million tons

U.S. Operations – Revenues Per Ton

PRB Average Price/Ton

$12.67

PRB

$12.40 – $12.90  

ILB Tons

~19 million tons

ILB

$41.75 – $43.75  

ILB Average Price/Ton

$42.39

Total U.S.

$18.90 – $19.30  

Essentially all of Peabody’s expected 2017 U.S. production

is priced as of March 31, 2017; 52% of 2018 volumes

are priced and 67% contracted (on a 2017 projected

sales volume basis).

U.S. Operations – Costs Per Ton

PRB

$9.75 – $10.25  

ILB

$31.25 – $33.25  

Total U.S.

$14.50 – $15.00  

Additional notes on following page

Like up on FACEBOOK
Market quotes are powered by
TradingView.com


Commodities ( Gold ) ( Silver ) ( Lithium )




BUZ INVESTORS Colorado Anti-Tattletale Tax Measure -- Overstock.com, Inc. (NASDAQ:OSTK) publicly urged Colorado legislators to pass an anti-tattletale tax bill to avoid a public outcry

Overstockcom Scheduled to Release Q1 2017 Financial Results on May 4, 2017

Chart | Calendar   | TRADE NOW | FORCAST | OVERSTOCK

Overstockcom Scheduled to Release Q1 2017 Financial Results on May 4, 2017

 BUZ INVESTORS PRESS RELEASE  Overstockcom Scheduled to Release Q1 2017   Overstock.com, Inc. (Common Shares - NASDAQ: OSTK / Series A Preferred

 BUZ INVESTORS PRESS RELEASE  Overstockcom Scheduled to Release Q1 2017   Overstock.com, Inc. (Common Shares – NASDAQ: OSTK / Series A Preferred – Medici Ventures’ t0 platform: OSTKP / Series B Preferred – OTCQB: OSTBP) is scheduled to release first quarter financial results for the period ending Mar. 31, 2017 on Thursday, May 4, 2017 after the market closes. The company has scheduled a conference call and webcast for 4:30 p.m. ET that day to discuss these results. The company will take questions via email prior to the call. Please email all questions in advance of the call to ir@overstock.com.




 Overstockcom Scheduled

>>>TRADE NOW<<<

Webcast information

To access the live webcast and presentation slides, go to http://investors.overstock.com. To listen to the conference call via telephone, dial (877) 673-5346 and enter conference ID 7574200 when prompted. Participants outside the U.S. or Canada who do not have Internet access should dial +1 (724) 498-4326 and enter the conference ID provided above.

Replay

A replay of the conference call will be available at http://investors.overstock.com starting two hours after the live call has ended. An audio replay of the webcast will be available via telephone starting at 7:30 p.m. ET on Thursday, May 4, 2017, through 7:30 p.m. ET on Thursday, May 18, 2017. To listen to the recorded webcast by phone, dial (855) 859-2056 and enter the conference ID provided above. Outside the U.S. or Canada, dial +1 (404) 537-3406 and enter the conference ID provided above.

About Overstockcom
Overstock.com, Inc. (Common Shares – NASDAQ: OSTK / Series A Preferred – Medici Ventures’ t0 platform: OSTKP / Series B Preferred – OTCQB: OSTBP) is an online retailer based in Salt Lake City, Utah that sells a broad range of products at low prices, including furniture, décor, rugs, bedding, jewelry, electronics, apparel, and more, as well as a marketplace providing customers access to hundreds of thousands of products from third-party sellers. Additional stores include Worldstock.com, dedicated to selling artisan-crafted products from around the world, and Main Street Revolution, supporting small-scale entrepreneurs in the U.S. by giving them access to our national customer base. Forbes ranked Overstock in its list of the Top 100 Most Trustworthy Companies in 2014. Overstock regularly posts information about the company and other related matters under Investor Relations on its website.

O, Overstock.com, O.com, O.co, Club O, Main Street Revolution, Worldstock and OVillage are registered trademarks of Overstock.com, Inc.  O.biz and Space Shift are also trademarks of Overstock.com, Inc.  Other service marks, trademarks and trade names which may be referred to herein are the property of their respective owners.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements include all statements other than statements of historical fact.  Additional information regarding factors that could materially affect results and the accuracy of the forward-looking statements contained herein may be found in the Company’s Form 10-K for the year ended December 31, 2016, which was filed with the SEC on March 3, 2017, and any subsequent filings with the SEC.

 

Like up on FACEBOOK


Ebates Coupons and Cash Back

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




RADCOM (NASDAQ: RDCM) is a first-mover and leading provider of NFV-ready service assurance and Customer Experience Management (

RADCOM Reports Fourth Quarter and Full Year 2016 Financial Results

Chart | Calendar   | TRADE NOW | RDCM

RADCOM Reports Fourth Quarter and Full Year 2016 Financial Results

BUZ INVESTORS RADCOM Reports Fourth Quarter   RADCOM Ltd. <span data-recalc-dims=(RDCM) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2016." width="300" height="103" srcset="https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/download-Small-1.jpg?resize=300%2C103 300w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/download-Small-1.jpg?resize=768%2C263 768w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/download-Small-1.jpg?w=854 854w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ INVESTORS RADCOM Reports Fourth Quarter   RADCOM Ltd. (RDCM) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2016.

“The fourth quarter marked a strong end to a great year for the Company, highlighted by our ability to reach the high-end of our guidance range,” commented Mr. Yaron Ravkaie, RADCOM’s CEO.  “In 2016, we made great progress with our top-tier customer deployments, continued our engagement with other leading global carriers, and focused on preparing the company for future growth by boosting our senior management team and ramping up our engineering capabilities.  We believe we have laid a solid foundation during 2016 to continue our momentum, as evidenced by our initial 2017 revenue guidance range of $36-$39 million.”

Fourth Quarter 2016 Financial Highlights

  • Revenues: Total revenues for the fourth quarter were $8.0 million, up 196% compared to $2.7 million in the fourth quarter of 2015.
  • Net Loss: GAAP net loss for the period was approximately $0.7 million, or $0.06 loss per diluted share, compared to a loss of $2.1 million, or $0.25 loss per diluted share for the fourth quarter of 2015.
  • Non-GAAP Net Income/(Loss):  Non-GAAP net income for the period was approximately $0.4 million, or $0.04 per diluted share, compared to a loss of $(1.6) million, or $(0.19) per diluted share for the fourth quarter of 2015.Both GAAP and non-GAAP results for the fourth quarter of 2016 included a $552,000, or $0.05 per diluted share, benefit related to grants from the Israel Innovation Authority (formerly Office of the Chief Scientist) compared to $576,000, or $0.07 per diluted share, in the fourth quarter of 2015.
  • Balance sheet: As of December 31, 2016, the Company had cash and cash equivalents of $42.9 million and no debt.




RADCOM Reports Fourth Quarter

>>>>TRADE NOW<<<

Full Year 2016 Financial Highlights

  • Revenues: Total revenues for the full year 2016 were $29.5 million, up 58% compared to $18.7 million in the full year 2015.
  • Net Income/(Loss): GAAP net income for the full year 2016 was approximately $1.9 million, or $0.18 per diluted share, compared to a loss of $(923,000), or $(0.11) per diluted share for the full year 2015.
  • Non-GAAP Net Income:  Non-GAAP net income for the period was approximately $4.8 million or $0.44 per diluted share, for the full year 2016, compared to $656,000, or $0.07 per diluted share for the full year 2015.Both GAAP and non-GAAP results for the full year 2016 included a $1.7 million, or $0.16 per diluted share, benefit related to grants from the Israel Innovation Authority compared to $1.6 million, or $0.18 per diluted share, in 2015.

Earnings Conference Call
RADCOM’s management will hold an interactive conference call today at 8:00 AM Eastern Time (15:00 Israel Time) to discuss the results and to answer participants’ questions. To join the call, please call one of the following numbers approximately five minutes before the call is scheduled to begin:

From the US (toll-free): + 1-888-668-9141

From other locations: +972-3-918-0609

For those unable to listen to the call at the time, a replay will be available from February 15th on RADCOM’s website.

About RADCOM

RADCOM (NASDAQ: RDCM) is a first-mover and leading provider of NFV-ready service assurance and customer experience management solutions for Communications Service Providers (CSPs). RADCOM’s software – MaveriQ – continuously monitors network performance and quality of services, to optimize user experience for CSPs’ subscribers. RADCOM specializes in solutions for next-generation mobile and fixed networks, including LTE, VoLTE, IMS and others. MaveriQ enables CSPs to smoothly migrate their networks to NFV by assuring physical, NFV-based and hybrid networks. For more information, please visit www.radcom.com.

Non-GAAP Information

Certain non-GAAP financial measures are included in this press release. These non-GAAP financial measures are provided to enhance the reader’s overall understanding of the Company’s financial performance. By excluding non-cash stock-based compensation that has been expensed in accordance with ASC Topic 718, inventory write-off and  non-cash write-off of importation taxes, the Company’s non-GAAP results provide information to both management and investors that is useful in assessing the Company’s core operating performance and in evaluating and comparing the Company’s results of operations on a consistent basis from period to period. These non-GAAP financial measures are also used by management to evaluate financial results and to plan and forecast future periods.  The presentation of this additional information is not meant to be considered a substitute for the corresponding financial measures prepared in accordance with GAAP.

Risks Regarding Forward-Looking Statements

Certain statements made herein that use words such as “estimate,” “project,” “intend,” “expect,” “‘believe”, “may”, “might”, “predict”, “potential”, “anticipate”, “plan” or similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. For example, when the Company discusses its momentum and revenue guidance for 2017 it is using foward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied by such statements, including, among others, changes in general economic and business conditions and specifically, decline in the demand for the Company’s products, inability to timely develop and introduce new technologies, products and applications, and loss of market share and pressure on prices resulting from competition. For additional information regarding these and other risks and uncertainties associated with the Company’s business, reference is made to the Company’s reports filed from time to time with the U.S. Securities and Exchange Commission. The Company does not undertake to revise or update any forward-looking statements for any reason.

 

Like up on FACEBOOK


Ebates Coupons and Cash Back

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




OTHER RELATED STORIES 

Amgen Reports First Quarter 2017 Financial Results

View printer-friendly version

Amgen Reports First Quarter 2017 Financial Results

BUZ INVESTORS PRESS RELEASE Amgen Reports First Quarter THOUSAND OAKS, Calif., April 26, 2017 /PRNewswire/ -- Amgen <span data-recalc-dims=(NASDAQ:AMGN) today announced financial results for the first quarter of 2017. Key results include:" width="300" height="225" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2016/11/amgen-stock-300x225.resized-1.jpg?resize=300%2C225 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2016/11/amgen-stock-300x225.resized-1.jpg?w=640 640w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ INVESTORS  PRESS RELEASE  Amgen Reports First Quarter Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2017. Key results include:

  • Total revenues decreased 1 percent versus the first quarter of 2016 to $5.5 billion.
  • GAAP earnings per share (EPS) increased 12 percent to $2.79 driven by higher operating margins.
    • GAAP operating income increased 8 percent to $2.6 billion and GAAP operating margin increased 4 percentage points to 49.8 percent.
  • Non-GAAP EPS increased 9 percent to $3.15 driven by higher operating margins.
    • Non-GAAP operating income increased 5 percent to $3.0 billion and non-GAAP operating margin increased 3 percentage points to 57.6 percent.
  • 2017 EPS guidance increased to $10.64-$11.32 on a GAAP basis and $12.00-$12.60 on a non-GAAP basis; total revenues guidance unchanged at $22.3-$23.1 billion.
  • The Company generated $2.2 billion of free cash flow in the first quarter versus $1.8 billion in the first quarter of 2016.




 Amgen Reports First Quarter

“We are well positioned for the long term with our newer products demonstrating volume growth around the world and our tight operational expense management of the Company,” said Robert A. Bradway, chairman and chief executive officer. “With robust Repatha® (evolocumab) outcomes data, we are working with payers to improve access to this important therapy for patients at risk for heart attacks and strokes.”

$Millions, except EPS and percentages Q1’17 Q1’16 YOY Δ
Total Revenues $ 5,464 $ 5,527 (1%)
GAAP Operating Income $ 2,591 $ 2,402 8%
GAAP Net Income $ 2,071 $ 1,900 9%
GAAP EPS $   2.79 $   2.50 12%
Non-GAAP Operating Income $ 2,995 $ 2,859 5%
Non-GAAP Net Income $ 2,333 $ 2,203 6%
Non-GAAP EPS $   3.15 $   2.90 9%
References in this release to “non-GAAP” measures, measures presented “on a non-GAAP basis” and to “free cash flow” (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations.

Product Sales Performance

  • Total product sales decreased 1 percent for the first quarter of 2017 versus the first quarter of 2016.

  • Neulasta® (pegfilgrastim) sales increased 2 percent as favorable changes in accounting estimates and net selling price were offset partially by lower unit demand.

  • Enbrel® (etanercept) sales decreased 15 percent due to the impact of competition as well as lower rheumatology and dermatology segment growth compared to prior quarters.

  • Aranesp® (darbepoetin alfa) sales decreased 4 percent as higher unit demand was more than offset by unfavorable changes in foreign exchange rates, inventory and net selling price.

  • Prolia® (denosumab) sales increased 21 percent driven by higher unit demand.

  • Sensipar/Mimpara® (cinacalcet) sales increased 15 percent driven primarily by net selling price.

  • XGEVA® (denosumab) sales increased 6 percent driven by higher unit demand.

  • EPOGEN® (epoetin alfa) sales decreased 10 percent driven by net selling price.

  • KYPROLIS® (carfilzomib) sales increased 23 percent driven by higher unit demand.

  • Nplate® (romiplostim) sales increased 9 percent driven by higher unit demand.

  • NEUPOGEN® (filgrastim) sales decreased 31 percent driven primarily by the impact of competition.

  • Vectibix® (panitumumab) sales increased 2 percent driven by higher unit demand, offset partially by unfavorable changes in foreign exchange rates.

  • Repatha sales increased driven by higher unit demand.

  • BLINCYTO® (blinatumomab) sales increased 26 percent driven by higher unit demand.

Product Sales Detail by Product and Geographic Region
$Millions, except percentages Q1’17 Q1’16 YOY Δ
US ROW TOTAL TOTAL TOTAL
Neulasta® $1,048 $162 $1,210 $1,183 2%
Enbrel® 1,118 63 1,181 1,385 (15%)
Aranesp® 278 233 511 532 (4%)
Prolia® 279 146 425 352 21%
Sensipar® / Mimpara® 337 84 421 367 15%
XGEVA® 298 104 402 378 6%
EPOGEN® 270 0 270 300 (10%)
KYPROLIS® 137 53 190 154 23%
Nplate® 97 57 154 141 9%
NEUPOGEN® 101 47 148 213 (31%)
Vectibix® 61 86 147 144 2%
Repatha® 33 16 49 16 *
BLINCYTO® 23 11 34 27 26%
Other** 15 42 57 47 21%
Total product sales $4,095 $1,104 $5,199 $5,239 (1%)
* Change in excess of 100%
** Other includes Bergamo, MN Pharma, IMLYGIC®and Corlanor®

Operating Expense, Operating Margin and Tax Rate Analysis

On a GAAP basis:

  • Total Operating Expenses decreased 8 percent, with all expense categories reflecting savings from our transformation and process improvement efforts. Cost of Sales margin improved by 0.2 percentage points driven primarily by manufacturing efficiencies, offset partially by product mix. Research & Development (R&D) expenses decreased 12 percent driven by a payment in the first quarter of 2016 related to a third-party collaboration agreement, as well as lower spending required to support certain later-stage clinical programs. Selling, General & Administrative (SG&A) expenses decreased 12 percent due to the expiration of ENBREL residual royalty payments and an acquisition charge in the first quarter of 2016, offset partially by investments in product launches.

  • Operating Margin improved by 4 percentage points to 49.8 percent.

  • Tax Rate decreased 0.1 percentage points as changes in the geographic mix of earnings were offset partially by lower tax benefits from share-based compensation payments.

On a non-GAAP basis:

  • Total Operating Expenses decreased 7 percent, with all expense categories reflecting savings from our transformation and process improvement efforts. Cost of Sales margin improved by 0.4 percentage points driven primarily by manufacturing efficiencies, offset partially by product mix. R&D expenses decreased 13 percent driven by a payment in the first quarter of 2016 related to a third-party collaboration agreement, as well as lower spending required to support certain later-stage clinical programs. SG&A expenses decreased 6 percent due to the expiration of ENBREL residual royalty payments, offset partially by investments in product launches.

  • Operating Margin improved by 3 percentage points to 57.6 percent.

  • Tax Rate decreased 0.4 percentage points as changes in the geographic mix of earnings were offset partially by lower tax benefits from share-based compensation payments.

$Millions, except percentages
GAAP Non-GAAP
Q1’17 Q1’16 YOY Δ Q1’17 Q1’16 YOY Δ
Cost of Sales $996 $1,018 (2%) $682 $707 (4%)
% of product sales 19.2% 19.4% (0.2)pts 13.1% 13.5% (0.4) pts
Research & Development $769 $872 (12%) $748 $858 (13%)
% of product sales 14.8% 16.6% (1.8) pts 14.4% 16.4% (2) pts
Selling, General & Administrative $1,064 $1,203 (12%) $1,039 $1,103 (6%)
% of product sales 20.5% 23.0% (2.5) pts 20.0% 21.1% (1.1) pts
Other $44 $32 38% $0 $0 NM
TOTAL Operating Expenses $2,873 $3,125 (8%) $2,469 $2,668 (7%)
Operating Margin
operating income as a % of product sales 49.8% 45.8% 4 pts 57.6% 54.6% 3 pts
Tax Rate 15.8% 15.9% (0.1) pts 18.5% 18.9% (0.4) pts
NM: Not Meaningful
pts: percentage points

Cash Flow and Balance Sheet

  • The Company generated $2.2 billion of free cash flow in the first quarter of 2017 versus $1.8 billion in the first quarter of 2016 driven by the timing of tax payments and higher net income.

  • The Company’s second quarter 2017 dividend of $1.15 per share declared on March 7, 2017, will be paid on June 8, 2017, to all stockholders of record as of May 17, 2017.

  • During the first quarter, the Company repurchased 3.4 million shares of common stock at a total cost of $555 million. At the end of the first quarter, the Company had $3.5 billion remaining under its stock repurchase authorization.

$Billions, except shares Q1’17 Q1’16 YOY Δ
Operating Cash Flow $2.4 $1.9 $0.5
Capital Expenditures 0.2 0.2 0.0
Free Cash Flow 2.2 1.8 0.5
Dividends Paid 0.8 0.8 0.1
Share Repurchase 0.6 0.7 (0.1)
Avg. Diluted Shares (millions) 741 760 (19)
Cash and Investments 38.4 34.7 3.7
Debt Outstanding 34.1 34.3 (0.2)
Stockholders’ Equity 30.6 28.7 2.0
Note: Numbers may not add due to rounding

2017 Guidance

For the full year 2017, the Company now expects:

  • Total revenues in the range of $22.3 billion to $23.1 billion, unchanged from previous guidance.

  • On a GAAP basis, EPS in the range of $10.64 to $11.32 and a tax rate in the range of 16 percent to 18 percent.

    • Previously, the Company expected GAAP EPS in the range of $10.45 to $11.31. Tax rate guidance is unchanged.

  • On a non-GAAP basis, EPS in the range of $12.00 to $12.60 and a tax rate in the range of 18.5 percent to 19.5 percent.

    • Previously, the Company expected non-GAAP EPS in the range of $11.80 to $12.60. Tax rate guidance is unchanged.

  • Capital expenditures to be approximately $700 million.

First Quarter Product and Pipeline Update
Key development milestones:
Clinical Program Indication Projected Milestone
Repatha Hyperlipidemia Regulatory submissions (CV outcomes data)
KYPROLIS Relapsed or refractory  multiple myeloma Phase 3 study initiation with DARZALEX® Q2 ’17
XGEVA Prevention of SREs in multiple myeloma Regulatory reviews
EVENITY™ (romosozumab) Postmenopausal osteoporosis July 19, 2017, PDUFA target action date in U.S.

Active controlled Phase 3 fracture data Q2 2017*

Erenumab (AMG 334) Migraine prevention Regulatory submissions
ABP 215

(biosimilar bevacizumab)

Oncology Regulatory reviews

Sept. 14, 2017, BsUFA target action date in U.S.

ABP 980

(biosimilar trastuzumab)

Breast cancer U.S. regulatory submission
Trade name provisionally approved by FDA; CV = cardiovascular; SRE = skeletal-related event; PDUFA = Prescription Drug User Fee Act; BsUFA = Biosimilar User Fee Act; *Event driven study

The Company provided the following updates on selected product and pipeline programs:

Repatha

  • In February, the European Commission (EC) approved a new 420 mg single-dose delivery option for Repatha.

  • In March, positive Phase 3 data from a cardiovascular outcomes study and a cognitive function study were presented at the American College of Cardiology 66th Annual Scientific Session.

KYPROLIS

  • In February,  the Phase 3 ENDEAVOR study showed KYPROLIS and dexamethasone reduced the risk of death by 21 percent and extended overall survival by an additional 7.6 months compared to Velcade® (bortezomib) and dexamethasone in relapsed or refractory multiple myeloma patients.

XGEVA

  • In April, a supplemental Biologics License Application (sBLA) was submitted to the U.S. Food and Drug Administration (FDA) and an application for a variation to the marketing authorization was submitted to the European Medicines Agency (EMA) for the prevention of SREs in patients with multiple myeloma.

BLINCYTO

  • In March, FDA accepted the sBLA for priority review for BLINCYTO to include overall survival data from the Phase 3 TOWER study. The application also included new data supporting the treatment of patients with Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

EVENITY

  • Primary analysis of an event driven active controlled Phase 3 fracture study (ARCH) in postmenopausal women with osteoporosis is expected in Q2 2017.

Erenumab

  • Regulatory submissions for migraine prevention are expected in Q2 2017.

CNP520

  • In February, Phase 3 enrollment commenced for CNP520, a small molecule beta-site amyloid precursor protein-cleaving enzyme-1 (BACE) inhibitor for the potential treatment of Alzheimer’s disease.

Parsabiv (etelcalcetide)

  • In February, FDA approved Parsabiv for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

AMG 157/MEDI9929 (tezepelumab)

  • In February, tezepelumab demonstrated a significant reduction in the rate of asthma exacerbations compared to placebo over the 52-week treatment period in patients with severe asthma in a Phase 2b study.

AMGEVITA™ (biosimilar adalimumab)

  • In March, EC granted marketing authorization for AMGEVITA™ (biosimilar adalimumab) in all available indications. AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-severe hidradenitis suppurativa; non-infectious intermediate, posterior and panuveitis; moderate-to-severe Crohn’s disease and moderate-to-severe ulcerative colitis. The EC also approved AMGEVITA for the treatment of certain pediatric inflammatory diseases, including moderate-to-severe Crohn’s disease (ages six and older), severe chronic plaque psoriasis (ages four and older), enthesitis-related arthritis (ages six and older) and polyarticular juvenile idiopathic arthritis (ages two and older).

ABP 980 (biosimilar trastuzumab)

  • In March, a Marketing Authorization Application was submitted to the EMA.

Erenumab and CNP520 are developed in collaboration with Novartis AG
EVENITY™ trade name is provisionally approved by FDA
EVENITY™ is developed in collaboration with UCB globally, as well as our joint venture partner Astellas in Japan
Tezepelumab is developed in collaboration with AstraZeneca
AMGEVITA™ is registered in the U.S. as AMJEVITA™
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.

Non-GAAP Financial Measures

In this news release, management has presented its operating results for the first quarters of 2017 and 2016, in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. In addition, management has presented its full year 2017 EPS and tax rate guidance in accordance with GAAP and on a non-GAAP basis. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, restructuring and certain other items from the related GAAP financial measures. Reconciliations for these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the news release. Management has also presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the first quarters of 2017 and 2016. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP.

The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor’s overall understanding of the financial performance and prospects for the future of the Company’s ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods.  The Company believes that FCF provides a further measure of the Company’s liquidity.

The Company uses the non-GAAP financial measures set forth in the news release in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




GBPUSD Pound Jumps to 1.25, Markets Eye Autumn

GBPUSD CLIMBS as UK borrowing hits lowest level since financial crisis

GBPUSD CLIMBS as UK borrowing hits lowest level since financial crisis




GBPUSD

BUZ INVESTORS  GBPUSD CLIMBS At 09:40 GMT, the pair is trading at 1.2824, with the Pound trading 0.26% higher against US Dollar from the New York close. In economic news, UK’s public sector net borrowing posted a more-than-expected deficit in March. The pair witnessed a high of 1.2827 and a low of 1.2771 during the session. Yesterday, the Pound traded marginally higher against the US Dollar in the New York session and ended at 1.2791. Immediate downside, the first support level is seen at 1.2785, while on the upside, the first resistance level is situated at 1.2846.



GBPUSD CLIMBS

British Pound | Data | Chart | Calendar | Forecast | News

TRADE NOW

The GBPUSD increased 0.0056 or 0.44% to 1.2841 on Tuesday April 25 from 1.2785 in the previous trading session. Historically, the British Pound reached an all time high of 2.86 in December of 1957 and a record low of 1.05 in February of 1985.

The GBPUSD spot exchange rate specifies how much one currency, the GBP, is currently worth in terms of the other, the USD. While the GBPUSD spot exchange rate is quoted and exchanged in the same day, the GBPUSD forward rate is quoted today but for delivery and payment on a specific future date. This page provides – British Pound – actual values, historical data, forecast, chart, statistics, economic calendar and news. British Pound – actual data, historical chart and calendar of releases – was last updated on April of 2017.

Pound Trading On A Stronger Footing, Ahead Of UK’s Retail Sales Data

For the 24 hours to 23:00 GMT, the GBP slightly declined against the USD and closed at 1.2474, following an apparent terrorist attack near the British Parliament at Westminster.

In the Asian session, at GMT0400, the pair is trading at 1.2481, with the GBP trading 0.06% higher against the USD from yesterday’s close.

The pair is expected to find support at 1.2433, and a fall through could take it to the next support level of 1.2385. The pair is expected to find its first resistance at 1.2517, and a rise through could take it to the next resistance level of 1.2553.

Like up on FACEBOOK


Ebates Coupons and Cash Back



major currencies: (EUR-USD) (USD-JPY) (USD-GBP) (USD-CHF), (USD-CAD), (AUD-USD)